When we compare the different vaccines (Pfizer, Sinopharm, Sputnik, and Pfizer–Sinopharm combination) at the same observation times 3 and 6 months after the second dose, before the third and one month, 3 and 6 months after the third dose in the subgroups that did not have COVID-19, analysis of the differences in anti-S1 antibody levels showed that participants who received SSP had statistically lower levels of anti-S1 IgG antibodies 6 months after the second dose than the groups receiving PPP and SSS (p < 0.001) (Figure 3A). The gene discussed is PSMD1; the disease is COVID-19.